• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    The advances of traditional Chinese medicine in the treatment of liver diseases in 2019

    2020-06-29 07:43:28MinCaoJingMiaoLiWangHaiZhaoLiuHuanTianCuiYuHongBian
    Traditional Medicine Research 2020年4期

    Min Cao, Jing Miao, Li Wang, Hai-Zhao Liu, Huan-Tian Cui, Yu-Hong Bian

    The advances of traditional Chinese medicine in the treatment of liver diseases in 2019

    Min Cao1#, Jing Miao2#, Li Wang3, Hai-Zhao Liu1, Huan-Tian Cui4, Yu-Hong Bian5*

    1Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China;2Department of Integrated Traditional and Western Medicine, Tianjin Second People’s Hospital, Tianjin 300192, China;3Department of Pharmacy, Tianjin Second People’s Hospital, Tianjin 300192, China;4Shandong Provincial Key Laboratory of Animal Cell and Developmental Biology, School of Life Sciences, Shandong University, Qingdao 250100, China;5College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

    Currently, the treatment of liver diseases remains an unsolved problem due to its complicated etiology and pathogenesis. Traditional Chinese medicine (TCM) has been used for liver disease treatment for thousands of years. Disease treatment using TCM compounds conforms to the concept of “holism”, which coincides with the complicated pathogenic mechanisms of liver diseases. However, the mechanisms have not been clearly explained due to the complex components and multi-targets, which is a big obstacle TCM’s popularity and application. In recent years, studying the mechanisms and identifying the novel ingredients in herbal medicines are becoming a hot spot for many researchers. Therefore, we obtained literature in PubMed and summarized the progress of TCM’s active ingredients and formulas in treating various liver diseases in 2019. Based on the literature, flavonoids, polysaccharides, saponins, and alkaloids, as well as Chinese medicine formulas, such as Ba-Bao pill and Yin-Chen-Hao decoction, have attracted much attention. In addition, we also focused on the application of new omics analysis techniques, such as metabolomics, network pharmacology, and other omics analyses in the study of TCM formulas.

    Traditional Chinese medicine, Liver diseases, Mechanism, Metabolomics, Network pharmacology, Omics analysis

    This article focuses on introducing the mechanism and application prospect of the active ingredients and formulas of traditional Chinese medicine in the treatment of liver diseases in 2019. Metabolomics, transcriptomics, network pharmacology, 16S rRNA gene sequencing, and other omic analyses have been widely used in many studies in the past year.

    This annual review summarizes the hot research mechanisms of traditional Chinese medicine in the treatment of liver disease, especially hepatitis, liver injury, non-alcoholic fatty liver disease, liver fibrosis, and hepatocellular carcinoma in 2019, which can provide a comprehensive description of the hot spots and ongoing research areas.

    Background

    Liver diseases, mainly including hepatitis, liver injury, non-alcoholic fatty liver disease (NAFLD), liver fibrosis, and hepatocellular carcinoma (HCC), have become a global threat for human health due to their high global prevalence rate and poor prognosis [1]. Currently, less effective medicines have been developed to control the progression of these liver diseases. Most patients need to receive lifelong medications, increasing the economic burden of the patients and their families. Moreover, long-term medication may cause hepatotoxicity and renal toxicity, which could exacerbate the liver damage and impair renal functions [2]. Therefore, identifying more effective, safer, and cheaper medicines for liver disease treatment is becoming a necessary research focus.

    Traditional Chinese medicine (TCM) has been used on liver diseases for thousands of years. However, the mechanisms have not been clearly explained due to the multi-compounds and multi-targets, which is a big obstacle for the wide use of TCM worldwide. Studying the mechanisms and identifying the novel ingredients could promote Chinese herbal medicine application. In addition, novel techniques such as metabolomics, network pharmacology, and other omics analyses have also been applied in this field. In 2019, the accumulated effort of researchers made great advances in studying the possible mechanisms of TCM on liver diseases.

    In this review, we summarized the research progress of several studies on the active ingredients and formulas in treating liver diseases. Papers focusing on TCM usage in liver diseases in PubMed were searched, with “l(fā)iver disease” and “traditional Chinese medicine” as the keywords. Generally, more than 700 articles were obtained from January 1, 2019 to December 31, 2019 in PubMed. We analyzed the number of literature published in different countries in 2019 via PubReMiner (https://hgserver2.amc.nl/cgi-bin/miner/miner2.cgi), a tool enabling the counting of the occurrence of certain search results within PubMed Search [3]. China contributed 679 papers in this field (Figure 1). Then, we summarized the top ten journals according to the number of published articles. Most of the articles were from the, which published 48 papers in 2019 (Figure 2). Moreover, we found that liver injury, NAFLD, liver fibrosis, and HCC were the mainly studied liver diseases (Figure 3).

    Figure 1 An analysis of the number of articles regarding the use of TCM in the treatment of liver diseases published in different countries in 2019. We searched in PubReMiner (https://hgserver2.amc.nl/cgi-bin/miner/miner2.cgi) using the keywords “l(fā)iver disease” and “traditional Chinese medicine” from 2019/01/01 to 2019/12/31 and analyzed the country distribution of the resulted articles.

    Figure 2 The top 10 journals with publications of TCM in the treatment of liver diseases in 2019. We searched in the PubReMiner (https://hgserver2.amc.nl/cgi-bin/miner/miner2.cgi) using the keywords “l(fā)iver disease” and “traditional Chinese medicine” from 2019/01/01 to 2019/12/31 to analyze the journal’s contribution.

    Figure 3 The top 12 keywords in TCM on liver disease therapy in 2019. We searched in the PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) database using the keywords “l(fā)iver disease” and “traditional Chinese medicine” from 2019/01/01 to 2019/12/31 to analyze the keyword contribution.

    Hepatitis

    Hepatitis B and C virus (HBV and HCV, respectively) are the major risk factors of liver injury, liver cirrhosis, and HCC. Currently, interferon and nucleoside (acid) analogs are the first-line clinical HBV and HCV treatment medicines. However, the covalently closed circular DNA of HBV could not be eliminated completely, and long-term medication could induce side effects, such as nephrotoxicity, bone toxicity, and medicine resistance [4–5]. Clinical studies also indicated that many patients experienced recurring HBV and HCV infection after medicine withdrawal [6–7]. In 2019, several articles showed that Chinese herbs and formulas could inhibit viral replication and control hepatitis progression. The saponins extracted from Jigucao (Hance) could inhibit the DNA replication of HBV by increasing the CD4+/CD3+T cell ratio and promoting interferon (IFN)-γ secretion [5]. Empirical formulas, especially the Bushen formula, consist of Huangqi (), Nüzhenzi (Lucidi), Yinyanghuo (Maxim), Huhuanglian (), and Qingpi (), which could significantly decrease the levels of Hepatitis B surface antigen in patients with HBV, compared with entecavir treatment alone. It also showed that the regulatory T cell number and the PD-L1 expression in dendritic cells were decreased in HBV-infected patients after the combination treatment with Bushen formula and entecavir[8]. The classical prescription Yin-Chen-Hao decoction, first described in the ancient book of Chinese medicine(), is composed of 18 g of Yinchen (), 12 g of Zhizi (), and 6 g of Dahuang (.), which could improve the clinical effect of patients with HBV [7]. In addition, a survey in Taiwan compared the effects and prognosis of patients with HCV that were treated with or without TCM, such as Danshen () and Huzhang (), and found that Chinese herbal medicine, as an adjuvant treatment, reduced the total mortality of patients and lowered the risk of cirrhosis and hepatoma development [9].

    Liver injury

    Liver injury is usually caused by exogenous substances, such as alcohol, medicines, and chemicals, which could cause liver metabolism disorders, oxidative stress, and toxification [10]. Nuclear factor 2-related factor 2 (Nrf2) is an important transcription factor of a series of detoxification and antioxidant defense genes in the liver, which plays an important role in protecting the liver against oxidative injury. Several TCMs have been proven to activate Nrf2-related signaling pathways and their downstream key antioxidant enzymes to protect against liver injuries in 2019 [11–12].

    Acute liver injury

    Quercetin is a naturally occurring polyphenolic flavonoid with a great antioxidant capacity and is commonly found in Huangqi ((Fisch.) Bunge.) [13], tomatoes, and berries [14], which could attenuate toosendanin-induced acute liver injury by promoting the Nrf2-GCL-GSH antioxidant signaling pathway [11]. Magnolol, the main chemical component ofHoupo (), could prevent alcohol-induced acute liver injury by activating the PI3K-Nrf2-peroxisome proliferator-activated receptor (PPAR)γ signaling pathway and inhibiting NOD-like receptor protein 3 inflammasome [15]. Chinese patent drug Ba-Bao pill (SFDA approval number of China: Z10940006) consists of eight constituents, including natural Niuhuang (), Shedan (snake gall), Lingyangjiao (), Shexiang (), and Sanqi (), which protected against acute ethanol-induced liver injury in mice by activating the Nrf2 pathway to decrease hepatocyte oxidative stress [16]. In addition, metabolomics and 16S rRNA gene sequencing indicated that the classical prescription Yin-Chen-Hao decoction, first described in the ancient book of Chinese medicine(), could prevent carbon tetrachloride (CCL4)-induced acute liver injury by regulating 3-hydroxybutyric acid production andandratios in the gut [17].

    Chronic liver injury

    Hot water extracts of Zhijuzi (), including 1.08% dihydromyricetin, 0.43% dihydroquercetin, and 1.40% quercetin, could alleviate lipid deposition and inflammation response in ethanol-induced chronic liver injury by modulating abnormalities in the gut-liver axis and inhibiting the TLR4 pathway [18]. A set prescription of the Tibetan medicine San-Wei-Gan-Jiang powder, first described in the(–), is composed of three herbs, including Ganjiang (Rosc.), Caodoukou (AHayat), and Roudoukou (), which could protect against CCL4-induced chronic liver injury in rats by dynamically regulating the Nrf2–Bach1 pathway [19]. The empirical formula “Compound T11” contains 14 Chinese medicines, including Huzhang (Sieb. et Zucc.), Sharen (Lour.), Dahuang (L.), Huanglian (Franch.), Huangqin (Georgi), and nine others, which could protect against CCL4-induced liver injury by enhancing matrix metalloproteinase-2 (MMP-2) and CD147 protein expression and reducing matrix metalloproteinase inhibitor-2 expression [20].

    Non-alcoholic fatty liver disease

    NAFLD is a liver manifestation of metabolic or insulin resistance syndrome. NAFLD pathogenesis, including insulin resistance, lipid metabolic changes, mitochondrial dysfunction, oxidative stress, and other factors, are not fully clear [21]. Currently, no effective therapeutic medicine has been developed for NAFLD treatment, as it is a metabolic disease with multi-systems disorder [22]. A variety of active ingredients and formulas of TCM had been proven effective in treating NAFLD. Triterpenic acid-enriched fractions mainly extracted from Qingqianliu ()could decrease hepatic lipid accumulation and attenuate insulin resistance by upregulating the PI3K-Akt-GSK3β pathway invivoand in vitro models of NAFLD [23]. Resveratrol, a major compound in many traditional Chinese herbs such as Huzhang () [24], could reduce insulin resistance, hepatic steatosis, oxidative stress, and hepatic inflammation in rats with hyperuricemia-induced NAFLD by activating the silent information regulator 1 pathway [25].

    The adenosine monophosphate-activated protein kinase (AMPK) is a heterotrimeric enzyme that plays an important role in maintaining energy metabolism homeostasis [26]. AMPK has been proven to regulate sterol regulatory element-binding protein 1 expression and acetyl-CoA carboxylases (ACC) in the liver. In vivo and in vitro studies showed that Midiexiang (Linn) could alleviate lipid metabolism in rats with orotic acid-induced NAFLD by regulating the AMPK-sterol regulatory element-binding protein 1c signaling pathway [27]. Swertiamarin is a secoiridoid glycoside mainly extracted from Zhangyacai ((Sieb. et Zucc.) Hook. Thoms. ex Clarke rude), which could regulate metabolic alterations in mice with fructose-induced NAFLD by downregulating regulatory SREBP-1, fatty acid synthase, and ACC1 expression [28]. Berberine, a protoberberine isoquinoline alkaloid mainly derived from Huanglian (Franch.), could ameliorate hyperlipidemia in rats with high-fat diet (HFD)-induced NAFLD by activating the SIRT3-AMPK-ACC pathway[29].

    In recent years, studying TCM’s mechanisms based on metabolomics, gut microbiota, and bioinformatics analyses aroused widespread concern because of the complex components of TCM. Based on metabolomics, quercetin could protect HFD-induced NAFLD in rats by regulating fatty acid-related metabolites [30]. MDG-1, a β-D-fructan polysaccharide mainly extracted from Maidong (), could modulate the gut-liver axis to regulate lipid metabolism in mice with HFD-induced NAFLD via increasing short-chain fatty acid-producing beneficial bacteria and activating AMPK expression [31]. Ilexhainanoside D and Ilexsaponin A1, the triterpenoid saponins mainly extracted from Dongqing (Merr.), could protect HFD-induced NAFLD in mice by reducing inflammation, regulating gut microbiota, and improving the intestinal barrier function [32]. Classical prescription Shen-Ling-Bai-Zhu powder is a famous formula derived fromthe ancient book of Chinese medicine(1078–1085 C.E.), mainly consists of Renshen (C. A. Mey.), Fuling (), Baizhu (Koidz.), Shanyao (Thunb), and Sharen (Lour.). Bioinformatics analysis showed that Shen-Ling-Bai-Zhu powder could protect HFD-induced NAFLD in rats by regulating hepatic microRNA expression profiles, mainly including miR-155-5p, miR-146b-5p, miR-132-3p, and miR-34a-5p [33]. In addition, Pan et al. proved that Shen-Ling-Bai-Zhu powder could also regulate hepatic lipid metabolism in HFD-fed rats by regulating glycerophospholipid and glycerolipid metabolism [34].

    Liver fibrosis

    Liver fibrosis is characterized by extracellular matrix (ECM) deposit accumulation with significant collagen fiber buildup, which is largely produced by activated hepatic stellate cells (HSCs)[35]. Several studies proved that HSC activation has been considered as the most important fibrosis-promoting factor [36]. In addition, transforming growth factor-beta1 (TGF-β1) secreted by activated HSCs is the most effective fibroblast, which induces ECM accumulation and collagen production [37]. Therefore, inhibiting HSCs activation, promoting HSC apoptosis, or regulating the TGF-β-related signaling pathways are the major mechanisms for liver fibrosis treatment. Jinyinhua (Flos)could inhibit HSC activation in mice with CCL4-induced liver fibrosis by activating the Nrf2 pathway [38]. Moreover, 4-hydroxy-2 (3H) -benzoxazolone, isolated from Laoshule (), could improve the condition of CCL4-induced liver fibrosis in rats by inhibiting the TGF-β1-Smad signaling pathway to inhibit HSC activation [39].Wenyujin ()could inhibit the activation and proliferation of HSCs in rats with pig-serum-induced hepatic fibrosis and reduce ECM accumulation by regulating the TGF-β-Smad signaling pathway and upregulating the MMP-2-matrix metalloproteinase inhibitor-1 ratio [40]. Salvianolic acid B, an effective water-soluble component of Danshen (.), could inhibit the activation of HSCs isolated from human liver specimens by downregulating the myocyte enhancer factor-2 signaling pathway [41]. Corilagin is a polyphenol mainly extracted from Zhuzicao (L.) [42], which could prevent liver fibrosis by blocking the miR-21-regulated TGF-β1-Smad signaling pathway in vivo and in vitro[43].

    In addition, transcriptomic analysis showed that schisandrin B, one of the bioactive components mainly extracted from Wuweizi (), could alleviate CCL4-induced liver fibrosis by regulating oxidation-reduction, endoplasmic reticulum stress, and apoptosis-related biological processes [44]. Based on metabolomics, bear bile powder could attenuate dimethylnitrosamine-induced liver fibrosis in rats by promoting PPARα and PPARγ expressions in the liver [45]. Network pharmacology analysis showed that the empirical formula Danshiliuhao granule, composed of Jinqiancao (), Huzhang (), Dahuang (), Zhizi (), Zhiqiao (), Muxiang (), Yanhusuo (), and Mangxiao (), could inhibit liver fibrosis by regulating multiple targets and multiple pathways, such as the PI3K-Akt-FoxO and Ras signaling pathways [46].

    Hepatocellular carcinoma

    Liver cancer is the second leading cause of cancer-related death. About 780,000 people worldwide die of liver cancer annually [47]. HCC accounts for approximately 90% of primary liver cancer[48]. However, most of the patients with HCC were diagnosed at the middle and late stage, which could not reach the standard of surgical operation. Furthermore, major cancer therapies, such as radiotherapy, chemotherapy, targeted therapeutics, and radiofrequency ablation, do not work well on HCC due to the hepatotoxicity and unresponsiveness to radio-chemotherapy [47, 49]. In addition, the first-line medicines for patients with HCC could cause adverse effects, including gastrointestinal reaction, anaphylaxis, myelosuppression, kidney damage, and neurovirulence [50].

    TCM has been proven to play an important role in cancer recurrence and metastasis prevention, toxicity reduction, and the prolonged survival of patients with cancer [49]. Several TCM active ingredients have been proven to have therapeutic effects on HCC by inhibiting cell proliferation and migration, and inducing cancer cell apoptosis.The ethanol extract of Nüzhenzi (.), which is rich in total phenylpropanoid glycosides and secoiridoids, could inhibit HCC cell invasion, migration, and tumor growth by regulating the expression of factors related to apoptosis and cell cycle arrestin vivo and in vitro[50]. Theethanol extracts of Mutong ((Thunb.) koidz seed), mainly including Akebia saponin D, Akebia saponin E, and α-hederin, could inhibit human HCC cell adhesion, migration, and invasion [51]. Aloperine, a quinolizidine alkaloid from Kudouzi (L.), could induce human HCC cell apoptosis and G2/M cell cycle arrest by inhibiting the PI3K-Akt signaling pathway [52]. Psoralen is the main active component of Buguzhi (), which could induce cell cycle arrest in the G1 phase and apoptosis, inhibit malignant proliferation of human HCC cells by triggering endoplasmic reticulum stress [53].In vitro and in vivo studies showed that dioscin, a natural steroidal saponin mainly extracted from Shuyu () [54], could inhibit proliferation and migration and induce apoptosis in human HCC cells by adjusting the TP53-inducible glycolysis and apoptosis regulator-mediated signaling pathway [55].

    In addition, the structural abnormalities of tumor vessels may reduce anticancer treatment efficacy. Normalizing the disordered tumor vasculature is a novel method for anticancer therapeutics. Huangqi () and Wenyujin () could promote vascular normalization in tumor-derived endothelial cells of human HCC by regulating CD34 and hypoxia-inducible factor-1α expressions [56]. Moreover, combination therapy with astragali polysaccharide and curcumin, the primary active constituents of Huangqi()andWenyujin() respectively, could inhibit tumor growth in orthotopic nude mice with HCC via improving the tumor vascular morphological structure and inducing tumor vascular normalization [57]. Emodin, aloe-emodin, and rhein are the main components of Dahuang (), which could inhibit the proliferation, migration, and angiogenesis and induce apoptosis of liver cancer cells by inhibiting signal transducer and activator of transcription 3 expression and phosphorylation [58].

    MiRNAs are generally considered to manage gene expression at the post-transcriptional level and are considered to be important physiologic disease progression regulators. The latest research showed that miRNAs play an important role in liver cancer occurrence and development, and they directly affect cell growth and metastasis by targeting specific protein-coding genes [59]. Luteolin, a natural flavonoid mainly extracted from Shanyao (Thunb.), could inhibit liver cancer cell proliferation by upregulating miR-6809-5p expression and downregulating flotillin 1expression [60]. Hydroxygenkwanin is a natural flavonoid mainly extracted from Yuanhua (), which could inhibit liver cancer cell proliferation and migration by inducing the expression of miR-320a, which, in turn, inhibits the expression of the forkhead box protein M1 transcription factor [48]. Geniposide is mainly extracted from Zhizi (Ellis), which could inhibit hepatoma cell proliferation and migration via inhibiting the Wnt-β-catenin and AKT cascades to target the downregulation of microRNA-224 [59].

    In addition, Saikosaponin D, an active ingredient mainly extracted from Chaihu (), could inhibit the growth and enhance the radio sensitivity of hepatoma cells by inducing autophagy [61]. Atractylon is a sesquiterpenoid mainly extracted from Cangzhu ((Thunb.) DC.) and Beicangzhu ((DC.) Koidz.), which could inhibit liver cancer cell migration and invasion by inhibiting epithelial-to-mesenchymal transition and downregulating MMP-2 and MMP-9 expressions to reduce the mitochondrial membrane potential (ΔΨm) and induce cancer cell apoptosis [62]. Chinese patent drug Shaoyao Ruangan formula (SFDA approval number of China: Z20100018) contains 19 Chinese herbal medicines, including Baihuasheshecao (Willd.), Huangqin (Georgi.), Qingyangshen (.), Wenyujin (Y. H. Chen et C. Ling.), Sanleng (Buch. -Ham.), and 14 more components,which could effectively inhibit tumor progression in mice with primary liver cancer by regulating intestinal flora homeostasis[63].

    Other liver diseases

    Hepatic encephalopathy (HE) is a neuropsychiatric disease caused by serious liver damage or failure. According to the research, 30–45% of patients with cirrhosis will develop into HE. Elevated blood ammonia levels and an abnormal electroencephalograph result are the common manifestations of HE. Hyperammonemia could impair brain metabolism, astrocyte volume regulation, and mitochondrial function, and may develop neuropsychological symptoms. Lycium barbarum polysaccharides, the major active component of Gouqizi (), could improve liver/brain injury and motor dysfunction in mice with HE by regulating the liver and brain MAPK pathways, TNF-α, interleukin-6, and ammonia [64]. Ba-Bao pill could alleviate hepatic encephalopathy in rats by reducing blood and brain ammonia levels and regulating the TLR4-MyD88-NF-κB pathway to induce anti-inflammatory effects [65].

    Acute liver failure (ALF) is a rare but life-threatening syndrome, which presents a rapid deterioration of liver function and potential multiorgan failure [66]. In vivo and in vitrostudies showed that the empirical formula Jie-Du-Hua-Yu formula, which consists of six herbs, including Chishao (), Yinchenhao (), Dahuang (), Yujin (), Baihuasheshecao (), and Shichangpu (), could treat lipopolysaccharide/D-galactosamine-induced ALF in rats by inhibiting the NF-κB-mediated inflammatory pathway [66]. Acute-on-chronic liver failure (ACLF) is a type of ALF, which is characterized by early chronic liver disease or cirrhosis combined with organ failure, and is associated with high short-term mortality [67][68]. The empirical formula Jieduan-Niwan formula contains ten Chinese herbs, including Yexiazhu (Linn.), Honghuayanhuangqi (Maxim.), Gualou (Maxim),Jinqiancao(Hance), and Hujisheng (Heyne), which could protect the liver and attenuate hepatocyte apoptosis in rats with ACLF by inhibiting the E2F1-mediated intrinsic apoptosis pathway [69]. The modified classic ancient formula Sini decoction consists of Wutou (), Gancao (), Shengjiang (), Wumei (), Renshen (), and other components, which could improve liver function and prolong the 12-week survival rate of patients with HBV-related ACLF [67].

    Conclusion and perspective

    Although Western medicine usually adopts symptomatic support to treat various chronic liver diseases, the current status of liver disease treatment is still not optimistic due to its complicated pathogenic factors and mechanisms [1]. TCM has accumulated a lot of experience in the liver disease treatment and achieved unique curative effects with the guiding concept of “holism” and the ideology of syndrome differentiation and treatment. However, the clinical curative effects of most TCM compounds are obvious, but there is lack of further laboratory experiments to prove its complex mechanics. Therefore, we summarized several researches on the active ingredients of traditional Chinese herbs used in liver disease treatment in 2019, which is mainly focused on their antioxidant effects to treat liver injury, lipid metabolism regulation to treat NAFLD, HSC inhibition to treat liver fibrosis, and inhibition of proliferation or promotion of apoptosis of liver cancer cells to treat HCC. In addition, TCM, especially the Chinese medicine formulas, is characterized by target-pathway-faceted integrated regulation because of its complex composition and structural types. Based on these findings, several researchers are committed to investigating more diversified ways to explore the specific mechanisms of TCM in treating various diseases. Therefore, metabolomics, transcriptomics, network pharmacology, 16S rRNA gene sequencing, and other omic analyses have been used in many studies. Metabolomics analysis could reflect the overall dynamic metabolic characteristics of biological systems and metabolic networks affected by pathologic stimulation or drug intervention [45]. Network pharmacology combines systemic biology, multi-directional pharmacology, bioinformatics, and other disciplines. Based on the “disease-gene-target-medicine” interaction network, it systematically observes the intervention and influence of medicines on the disease network, reflecting the new trend of systematic research of compound Chinese medicine in the era of big data [70]. The use of new omics analysis is in accordance with the concept of “holism” and could provide systematic views for future studies on TCM mechanisms [71].

    1. Shi MJ, Dong BS, Yang WN, et al. Preventive and therapeutic role of Tanshinone A in hepatology. Biomed Pharmacother 2019, 112: 108676.

    2. Sun D, Zhu L, Yao D, et al. Recent progress in potential anti-hepatitis B virus agents: structural and pharmacological perspectives. Eur J Med Chem 2018, 147: 205–217.

    3. Holleman F, Uijldert M, Donswijk LF, et al. Productivity of authors in the field of diabetes: bibliographic analysis of trial publications. BMJ 2015, 351: h2638.

    4. Wong GL, Seto WK, Wong VW, et al. Review article: long-term safety of oral anti-viral treatment for chronic hepatitis B. Aliment Pharmacol Ther 2018, 47: 730–737.

    5. Yao X, Li Z, Gong X, et al. Total saponins extracted from Abrus cantoniensis Hance suppress hepatitis B virus replication in vitro and in rAAV8-1.3HBV transfected mice. J Ethnopharmacol 2020, 249: 112366.

    6. Chi H, Li Z, Hansen BE, et al. Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy. Clin Gastroenterol Hepatol 2019, 17: 182–191 e181.

    7. Xu L, Xie T, Shen T, et al. Yinchenhao decoction for chronic hepatitis B: protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2019, 98: e14648.

    8. Ji LS, Gao QT, Guo RW, et al. Immunomodulatory effects of combination therapy with Bushen formula plus entecavir for chronic hepatitis B patients. J Immunol Res 2019, 2019: 8983903.

    9. Tsai FJ, Cheng CF, Chen CJ, et al. Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 2019, 57: 30–38.

    10. Odeyemi S, Dewar J. Repression of Acetaminophen-induced hepatotoxicity in HepG2 cells by polyphenolic compounds from(L.f.) R.H. Archer. Molecules 2019, 24.

    11. Jin Y, Huang ZL, Li L, et al. Quercetin attenuates toosendanin-induced hepatotoxicity through inducing the Nrf2/GCL/GSH antioxidant signaling pathway. Acta Pharmacol Sin 2019, 40: 75–85.

    12. Kwon SH, Lee SR, Park YJ, et al. Suppression of 6-hydroxydopamine-induced oxidative stress by hyperoside via activation of Nrf2/HO-1 signaling in dopaminergic neurons. Int J Mol Sci 2019, 20.

    13. Wang Y, Dong B, Xue W, et al. Anticancer effect ofon cholangiocarcinoma in vitro and its mechanism via network pharmacology. Med Sci Monit 2020, 26: e921162.

    14. Rauf A, Imran M, Khan IA, et al. Anticancer potential of quercetin: a comprehensive review. Phytother Res 2018, 32: 2109–2130.

    15. Liu X, Wang Y, Wu D, et al. Magnolol prevents acute alcoholic liver damage by activating PI3K/Nrf2/PPARgamma and inhibiting NLRP3 signaling pathway. Front Pharmacol 2019, 10: 1459.

    16. Yu Y, Tian ZQ, Liang L, et al. Ba-Bao Dan attenuates acute ethanol-induced liver injury via Nrf2 activation and autophagy. Cell Biosci 2019, 9: 80.

    17. Liu F, Sun Z, Hu P, et al. Determining the protective effects of Yin-Chen-Hao Tang against acute liver injury induced by carbon tetrachloride using 16S rRNA gene sequencing and LC/MS-based metabolomics. J Pharm Biomed Anal 2019, 174: 567–577.

    18. Qiu P, Dong Y, Zhu T, et al. Semen hoveniae extract ameliorates alcohol-induced chronic liver damage in rats via modulation of the abnormalities of gut-liver axis. Phytomedicine 2019, 52: 40–50.

    19. Chen Z, Zhao Y, Song C, et al. SanWeiGanJiang San relieves liver injury via Nrf2/Bach1. J Ethnopharmacol 2019, 251: 112445.

    20. Xu H, Yang N, Zhang Z, et al. Expression of matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and CD147 in the traditional Chinese medicine “Compound T11” for treatment of chronic liver injury. Pharmacology 2019, 103: 128–135.

    21. Deng Y, Tang K, Chen R, et al. Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. Exp Ther Med 2019, 17: 2091–2098.

    22. Hossain N, Kanwar P, Mohanty SR. A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD. Gastroenterol Res Pract 2016, 2016: 7109270.

    23. Zheng X, Zhao MG, Jiang CH, et al. Triterpenic acids-enriched fraction fromattenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3beta pathway. Phytomedicine 2020, 66: 153130.

    24. Wang YL, Horng CT, Hsieh MT, et al. Autophagy and apoptotic machinery caused byextract in cisplatinresistant human oral cancer CAR cells. Oncol Rep 2019, 41: 2549–2557.

    25. Xu K, Liu S, Zhao X, et al. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomed Pharmacother 2019, 110: 844–849.

    26. Park YJ, Lee GS, Cheon SY, et al. The anti-obesity effects of Tongbi-san in a high-fat diet-induced obese mouse model. BMC Complement Altern Med 2019, 19: 1.

    27. Wang SJ, Chen Q, Liu MY, et al. Regulation effects of rosemary (Linn.) on hepatic lipid metabolism in OA induced NAFLD rats. Food Funct 2019, 10: 7356–7365.

    28. Yang Y, Li J, Wei C, et al. Amelioration of nonalcoholic fatty liver disease by swertiamarin in fructose-fed mice. Phytomedicine 2019, 59: 152782.

    29. Zhang YP, Deng YJ, Tang KR, et al. Berberine ameliorates high-fat diet-induced non-alcoholic fatty liver disease in rats via activation of SIRT3/AMPK/ACC pathway. Curr Med Sci 2019, 39: 37–43.

    30. Xu Y, Han J, Dong J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development. Int J Mol Sci 2019, 20.

    31. Wang X, Shi L, Wang X, et al. MDG-1, anpolysaccharide, restrains process of non-alcoholic fatty liver disease via modulating the gut-liver axis. Int J Biol Macromol 2019, 141: 1013–1021.

    32. Zhao W, Xiao M, Yang J, et al. The combination of ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine 2019, 63: 153039.

    33. Pan M, Deng Y, Zheng C, et al. Chinese herbal medicine formula Shenling Baizhu San ameliorates high-fat diet-induced NAFLD in rats by modulating hepatic microRNA expression profiles. Evid Based Complement Alternat Med 2019, 2019: 8479680.

    34. Deng Y, Pan M, Nie H, et al. Lipidomic analysis of the protective effects of Shenling Baizhu San on non-alcoholic fatty liver disease in rats. Molecules 2019, 24.

    35. Wang A, Zhou F, Li D, et al. Gamma-mangostin alleviates liver fibrosis through sirtuin 3-superoxide-high mobility group box 1 signaling axis. Toxicol Appl Pharmacol 2019, 363: 142–153.

    36. Zhang Z, Guo M, Shen M, et al. Oroxylin A regulates the turnover of lipid droplet via downregulating adipose triglyceride lipase (ATGL) in hepatic stellate cells. Life Sci 2019, 238: 116934.

    37. Wang R, Song F, Li S, et al. Salvianolic acid A attenuates CCl4-induced liver fibrosis by regulating the PI3K/AKT/mTOR, Bcl-2/Bax and caspase-3/cleaved caspase-3 signaling pathways. Drug Des Devel Ther 2019, 13: 1889–1900.

    38. Chang ZY, Chen CC, Liu HM, et al. Positive effects of Ger-Gen-Chyn-Lian-Tang on cholestatic liver fibrosis in bile duct ligation-challenged mice. Int J Mol Sci 2019, 20.

    39. Sun X, Huang X, Zhu X, et al. HBOA ameliorates CCl4-incuded liver fibrosis through inhibiting TGF-beta1/Smads, NF-kappaB and ERK signaling pathways. Biomed Pharmacother 2019, 115: 108901.

    40. Xie H, Su D, Zhang J, et al. Raw and vinegar processedregulates hepatic fibrosis via bloking TGF-beta/Smad signaling pathways and up-regulation of MMP-2/TIMP-1 ratio. J Ethnopharmacol 2020, 246: 111768.

    41. Zhang W, Ping J, Zhou Y, et al. Salvianolic acid B inhibits activation of human primary hepatic stellate cells through downregulation of the myocyte enhancer factor 2 signaling pathway. Front Pharmacol 2019, 10: 322.

    42. Li X, Deng Y, Zheng Z, et al. Corilagin, a promising medicinal herbal agent. Biomed Pharmacother 2018, 99: 43–50.

    43. Zhou X, Xiong J, Lu S, et al. Inhibitory effect of corilagin on miR-21-regulated hepatic fibrosis signaling pathway. Am J Chin Med 2019, 47: 1541–1569.

    44. Zhang H, Chen Q, Dahan A, et al. Transcriptomic analyses reveal the molecular mechanisms of schisandrin B alleviates CCl4-induced liver fibrosis in rats by RNA-sequencing. Chem Biol Interact 2019, 309: 108675.

    45. Zheng M, Li YY, Wang GF, et al. Protective effect of cultured bear bile powder against dimethylnitrosamine-induced hepatic fibrosis in rats. Biomed Pharmacother 2019, 112: 108701.

    46. Tao Y, Tian K, Chen J, et al. Network pharmacology-based prediction of the active compounds, potential targets, and signaling pathways involved in Danshiliuhao granule for treatment of liver fibrosis. Evid Based Complement Alternat Med 2019, 2019: 2630357.

    47. Chou LF, Chen CY, Yang WH, et al. Suppression of hepatocellular carcinoma progression through FOXM1 and EMT inhibition via hydroxygenkwanin-induced miR-320a expression. Biomolecules 2019, 10.

    48. Zhang H, Li JC, Luo H, et al. Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways. Phytomedicine 2019, 59: 152759.

    49. Zhang JH, Zheng C, Zhu XJ, et al. Ganji formulation for patients with hepatocellular carcinoma who have undergone surgery: a multicenter, randomized, double-blind, controlled trial. Evid Based Complement Alternat Med 2019, 2019: 9492034.

    50. Tian G, Chen J, Luo Y, et al. Ethanol extract ofait. leaves suppressed hepatocellular carcinoma in vitro and in vivo. Cancer Cell Int 2019, 19: 246.

    51. Lu WL, Yang T, Song QJ, et al.(Thunb.) Koidz seed extract inhibits human hepatocellular carcinoma cell migration and invasion in vitro. J Ethnopharmacol 2019, 234: 204–215.

    52. Liu JS, Huo CY, Cao HH, et al. Aloperine induces apoptosis and G2/M cell cycle arrest in hepatocellular carcinoma cells through the PI3K/Akt signaling pathway. Phytomedicine 2019, 61: 152843.

    53. Wang X, Peng P, Pan Z, et al. Psoralen inhibits malignant proliferation and induces apoptosis through triggering endoplasmic reticulum stress in human SMMC7721 hepatoma cells. Biol Res 2019, 52: 34.

    54. Chen B, Zhou S, Zhan Y, et al. Dioscin inhibits the invasion and migration of hepatocellular carcinoma HepG2 cells by reversing TGF-beta1-induced epithelial-mesenchymal transition. Molecules 2019, 24.

    55. Mao Z, Han X, Chen D, et al. Potent effects of dioscin against hepatocellular carcinoma through regulating TP53-induced glycolysis and apoptosis regulator (TIGAR)-mediated apoptosis, autophagy, and DNA damage. Br J Pharmacol 2019, 176: 919–937.

    56. Zang W, Bian H, Huang X, et al. Traditional Chinese medicine (TCM)andpromote vascular normalization in tumor-derived endothelial cells of human hepatocellular carcinoma. Anticancer Res 2019, 39: 2739–2747.

    57. Tang D, Zhang S, Shi X, et al. Combination of astragali polysaccharide and curcumin improves the morphological structure of tumor vessels and induces tumor vascular normalization to inhibit the growth of hepatocellular carcinoma. Integr Cancer Ther 2019, 18: 1534735418824408.

    58. Tan ZB, Fan HJ, Wu YT, et al. Rheum palmatum extract exerts anti-hepatocellular carcinoma effects by inhibiting signal transducer and activator of transcription 3 signaling. J Ethnopharmacol 2019, 232: 62–72.

    59. Yu X, Wang Y, Tao S, et al. Geniposide plays anti-tumor effects by down-regulation of microRNA-224 in HepG2 and Huh7 cell lines. Exp Mol Pathol 2020, 112: 104349.

    60. Yang PW, Lu ZY, Pan Q, et al. MicroRNA-6809-5p mediates luteolin-induced anticancer effects against hepatoma by targeting flotillin 1. Phytomedicine 2019, 57: 18–29.

    61. Tian YD, Lin S, Yang PT, et al. Saikosaponin-d increases the radiosensitivity of hepatoma cells by adjusting cell autophagy. J Cancer 2019, 10: 4947–4953.

    62. Cheng Y, Chen T, Yang X, et al. Atractylon induces apoptosis and suppresses metastasis in hepatic cancer cells and inhibits growth in vivo. Cancer Manag Res 2019, 11: 5883–5894.

    63. Zhen H, Qian X, Fu X, et al. Regulation of Shaoyao Ruangan mixture on intestinal flora in mice with primary liver cancer. Integr Cancer Ther 2019, 18: 1534735419843178.

    64. Sun X, Lv Y, Huang L, et al. Pro-inflammatory cytokines serve as communicating molecules between the liver and brain for hepatic encephalopathy pathogenesis andpolysaccharides protection. J Ethnopharmacol 2020, 248: 112357.

    65. Lu L, Wu C, Lu BJ, et al. Ba-Bao Dan cures hepatic encephalopathy by decreasing ammonia levels and alleviating inflammation in rats. J Ethnopharmacol 2020, 249: 112301.

    66. Qiu H, Mao D, Tang N, et al. The underlying mechanisms of Jie-Du-Hua-Yu granule for protecting rat liver failure. Drug Des Devel Ther 2019, 13: 589–600.

    67. Luo JX, Zhang Y, Hu XY, et al. The effect of modified Sini decoction on survival rates of patients with hepatitis B virus related acute-on-chronic liver failure. Evid Based Complement Alternat Med 2019, 2019: 2501847.

    68. Ramzan M, Iqbal A, Murtaza HG, et al. Comparison of CLIF-C ACLF score and MELD score in predicting ICU mortality in patients with acute-on-chronic liver failure. Cureus 2020, 12: e7087.

    69. Yang W, Hao Y, Hou W, et al. Jieduan-Niwan formula reduces liver apoptosis in a rat model of acute-on-chronic liver failure by regulating the E2F1-mediated intrinsic apoptosis pathway. Evid Based Complement Alternat Med 2019, 2019: 8108503.

    70. Li S, Qian Y, Xie R, et al. Exploring the protective effect of ShengMai-Yin and Ganmaidazao decoction combination against type 2 diabetes mellitus with nonalcoholic fatty liver disease by network pharmacology and validation in KKAy mice. J Ethnopharmacol 2019, 242: 112029.

    71. Liu F, Wang M, Wang Y, et al. Metabonomics study on the hepatoprotective effect of panax notoginseng leaf saponins using UPLC/Q-TOF-MS analysis. Am J Chin Med 2019, 47: 559–575.

    :

    Yu-Hong Bian conceived of the presented idea; Min Cao and Jing Miao contributed to the manuscript preparation and modification with support from Yu-Hong Bian; Min Cao contributed to the hepatitis, liver injury, non-alcoholic fatty liver disease as well as conclusion and perspective in the manuscript; Jing Miao contributed to the abstract, liver fibrosis, hepatocellular carcinoma and other liver diseases in the manuscript; Li Wang, Hai-Zhao Liu and Huan-Tian Cui were responsible for searching and screening all of the literatures; all authors provided critical feedback and helped revise the final manuscript.

    :

    The authors declare no conflicts of interest.

    :

    This study was supported by Science and Technology Projects in Key Fields of Traditional Chinese Medicine of Tianjin Municipal Health Commission (No. 2020006); Tianjin Administration of Traditional Chinese Medicine, Integrated Chinese and Western Medicine Scientific Research Project of Tianjin Municipal Health Commission (No. 2017073).

    :

    TCM, traditional Chinese medicine; NAFLD, non-alcoholic fatty liver disease; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; Nrf2, nuclear factor 2-related factor 2; MMP-2, matrix metalloproteinase-2; AMPK, adenosine monophosphate-activated protein kinase; ACC, acetyl-CoA carboxylases; HFD, high-fat diet; ECM, extracellular matrix; HSC, hepatic stellate cell; TGF-β1, transforming growth factor-beta1; PPAR, peroxisome proliferator-activated receptor; HE, hepatic encephalopathy; ALF, acute liver failure; ACLF, acute-on-chronic liver failure.

    :

    Min Cao, Jing Miao, Li Wang, et al. The advances of traditional Chinese medicine in the treatment of liver diseases in 2019. Traditional Medicine Research 2020, 5 (4): 261–271.

    : Rui-Wang Zhao.

    :13 April 2020,

    14 May 2020,

    : 25 May 2020.

    #These authors are co-first authors on this work.

    Yu-Hong Bian. College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, No.10 Poyanghu Road, Jinghai District, Tianjin 301617, China. E-mail: bianyuhong_2012@163.com.

    10.12032/TMR20200520182

    亚洲一级一片aⅴ在线观看| 亚洲人成网站在线观看播放| 久久久精品区二区三区| 九色亚洲精品在线播放| 最近2019中文字幕mv第一页| 国产无遮挡羞羞视频在线观看| 蜜桃国产av成人99| 亚洲精品国产av蜜桃| 黄色视频在线播放观看不卡| 大香蕉97超碰在线| av在线播放精品| 亚洲情色 制服丝袜| 啦啦啦在线观看免费高清www| 五月伊人婷婷丁香| 22中文网久久字幕| 午夜福利网站1000一区二区三区| 亚洲精品美女久久av网站| 少妇的逼水好多| 99国产精品免费福利视频| 亚洲成av片中文字幕在线观看 | 丰满迷人的少妇在线观看| 有码 亚洲区| 国产日韩一区二区三区精品不卡| 久久 成人 亚洲| 欧美 亚洲 国产 日韩一| 久久国产亚洲av麻豆专区| 午夜福利视频精品| 精品国产国语对白av| 春色校园在线视频观看| 色婷婷久久久亚洲欧美| 少妇 在线观看| 飞空精品影院首页| 极品少妇高潮喷水抽搐| 在线观看免费视频网站a站| 成年人免费黄色播放视频| 免费高清在线观看日韩| 99视频精品全部免费 在线| 人成视频在线观看免费观看| 国产精品偷伦视频观看了| 日韩制服骚丝袜av| 少妇的逼好多水| 亚洲,一卡二卡三卡| a级毛片黄视频| av在线老鸭窝| 亚洲欧美一区二区三区黑人 | 国产成人免费无遮挡视频| 国产一级毛片在线| 亚洲av电影在线进入| 日韩不卡一区二区三区视频在线| 丰满少妇做爰视频| 亚洲国产看品久久| 亚洲一区二区三区欧美精品| 天堂8中文在线网| 国产 精品1| 日韩电影二区| 2022亚洲国产成人精品| 久久青草综合色| 999精品在线视频| 久久久久久久久久成人| 国产国语露脸激情在线看| 黄色毛片三级朝国网站| 在线观看人妻少妇| 母亲3免费完整高清在线观看 | 免费观看性生交大片5| 超碰97精品在线观看| 亚洲精品美女久久久久99蜜臀 | 日本91视频免费播放| 免费高清在线观看日韩| 午夜激情久久久久久久| 国产日韩欧美视频二区| 在线天堂中文资源库| 日本午夜av视频| 亚洲美女搞黄在线观看| 美女脱内裤让男人舔精品视频| 亚洲综合色惰| 老司机影院成人| 精品一区二区三卡| 大香蕉久久成人网| 嫩草影院入口| 久久久a久久爽久久v久久| 精品熟女少妇av免费看| 多毛熟女@视频| 国产精品99久久99久久久不卡 | tube8黄色片| 免费女性裸体啪啪无遮挡网站| 国产精品国产三级国产av玫瑰| 又黄又粗又硬又大视频| 考比视频在线观看| 国产一区二区在线观看日韩| 久久国内精品自在自线图片| 国产精品麻豆人妻色哟哟久久| 日本-黄色视频高清免费观看| 啦啦啦在线观看免费高清www| 下体分泌物呈黄色| 国产成人一区二区在线| 极品人妻少妇av视频| 人妻人人澡人人爽人人| 久久久精品免费免费高清| 亚洲一区二区三区欧美精品| 免费观看无遮挡的男女| 国产日韩欧美在线精品| 男女啪啪激烈高潮av片| 亚洲,一卡二卡三卡| 国产在线一区二区三区精| 最近中文字幕2019免费版| 一本色道久久久久久精品综合| 国产亚洲精品久久久com| 日本欧美视频一区| 成人手机av| 91在线精品国自产拍蜜月| 国产深夜福利视频在线观看| 纵有疾风起免费观看全集完整版| 午夜免费鲁丝| 久久久久久人妻| 最近中文字幕2019免费版| 在线观看三级黄色| 亚洲精品第二区| 亚洲在久久综合| 久久久久精品久久久久真实原创| 国产精品嫩草影院av在线观看| 亚洲丝袜综合中文字幕| 日韩伦理黄色片| 大片免费播放器 马上看| 国产亚洲精品第一综合不卡 | 亚洲精品色激情综合| 国精品久久久久久国模美| 久久人人爽人人爽人人片va| 99国产精品免费福利视频| 看十八女毛片水多多多| 制服丝袜香蕉在线| 国产男女超爽视频在线观看| 免费观看av网站的网址| 国产一区二区三区综合在线观看 | 色哟哟·www| 又黄又粗又硬又大视频| 999精品在线视频| 蜜桃在线观看..| 免费观看av网站的网址| 日韩制服骚丝袜av| 人人妻人人添人人爽欧美一区卜| av不卡在线播放| 亚洲美女搞黄在线观看| 伦精品一区二区三区| 日本黄大片高清| 亚洲一级一片aⅴ在线观看| 国产精品久久久久久av不卡| 久久久久久久亚洲中文字幕| 亚洲精品久久久久久婷婷小说| 久久精品久久精品一区二区三区| 久久精品久久久久久久性| 国产精品久久久av美女十八| 亚洲精华国产精华液的使用体验| 精品国产露脸久久av麻豆| 一级片免费观看大全| 日本色播在线视频| 激情五月婷婷亚洲| 久久久久网色| 97在线人人人人妻| 91精品三级在线观看| 亚洲精品视频女| 精品久久蜜臀av无| 久久精品国产综合久久久 | 18在线观看网站| 国产亚洲午夜精品一区二区久久| 亚洲欧美清纯卡通| 久久精品国产亚洲av天美| 宅男免费午夜| 桃花免费在线播放| 亚洲精品中文字幕在线视频| 国产福利在线免费观看视频| 午夜福利视频精品| 欧美激情 高清一区二区三区| 久久久久精品久久久久真实原创| 秋霞在线观看毛片| 国产免费福利视频在线观看| 免费观看性生交大片5| av在线老鸭窝| 欧美bdsm另类| 人妻系列 视频| 国产精品.久久久| 欧美精品国产亚洲| 老熟女久久久| 蜜臀久久99精品久久宅男| 2018国产大陆天天弄谢| 最近手机中文字幕大全| 亚洲精品成人av观看孕妇| 久久久国产欧美日韩av| 91精品三级在线观看| 亚洲精品自拍成人| 成人国语在线视频| 亚洲婷婷狠狠爱综合网| 国产精品久久久久久精品古装| 赤兔流量卡办理| 永久免费av网站大全| 女人精品久久久久毛片| 国产1区2区3区精品| 三级国产精品片| 久久这里有精品视频免费| 欧美xxⅹ黑人| 卡戴珊不雅视频在线播放| 午夜影院在线不卡| 看非洲黑人一级黄片| 亚洲国产最新在线播放| 亚洲,欧美,日韩| 日韩大片免费观看网站| 如何舔出高潮| 亚洲精品视频女| 国产精品久久久久久av不卡| 久久精品aⅴ一区二区三区四区 | 自拍欧美九色日韩亚洲蝌蚪91| 三级国产精品片| 亚洲成人av在线免费| 精品一区在线观看国产| 乱码一卡2卡4卡精品| 亚洲精品日韩在线中文字幕| 我要看黄色一级片免费的| 亚洲,欧美精品.| 国产成人免费观看mmmm| 亚洲精品456在线播放app| 中文字幕另类日韩欧美亚洲嫩草| 啦啦啦中文免费视频观看日本| 亚洲国产毛片av蜜桃av| 日韩精品有码人妻一区| 国产精品99久久99久久久不卡 | 欧美+日韩+精品| 一区二区av电影网| 建设人人有责人人尽责人人享有的| 久久久久久久久久人人人人人人| 天堂8中文在线网| 国产精品久久久av美女十八| 国产精品一国产av| 水蜜桃什么品种好| 久久女婷五月综合色啪小说| 人人妻人人添人人爽欧美一区卜| 午夜免费男女啪啪视频观看| 自拍欧美九色日韩亚洲蝌蚪91| 纯流量卡能插随身wifi吗| 边亲边吃奶的免费视频| 夜夜骑夜夜射夜夜干| 欧美+日韩+精品| 中文精品一卡2卡3卡4更新| 丝袜在线中文字幕| 在线观看免费日韩欧美大片| 欧美xxxx性猛交bbbb| 伦理电影大哥的女人| 成人国语在线视频| a 毛片基地| 亚洲丝袜综合中文字幕| 免费女性裸体啪啪无遮挡网站| 亚洲精品乱久久久久久| 亚洲欧美清纯卡通| tube8黄色片| 国产精品久久久久久久电影| 女人精品久久久久毛片| 久久国内精品自在自线图片| av在线老鸭窝| 成人毛片60女人毛片免费| 少妇的逼好多水| 日韩 亚洲 欧美在线| av视频免费观看在线观看| 国产午夜精品一二区理论片| 女人精品久久久久毛片| 亚洲图色成人| 日韩中字成人| 免费看av在线观看网站| 一级,二级,三级黄色视频| 丰满少妇做爰视频| 人妻一区二区av| 91aial.com中文字幕在线观看| 我要看黄色一级片免费的| 赤兔流量卡办理| 欧美日韩成人在线一区二区| 欧美日韩av久久| 99国产综合亚洲精品| 国产精品女同一区二区软件| 亚洲精华国产精华液的使用体验| 欧美另类一区| 男女无遮挡免费网站观看| 亚洲国产av影院在线观看| 欧美丝袜亚洲另类| 伊人亚洲综合成人网| 人妻人人澡人人爽人人| 老司机影院毛片| 日韩成人av中文字幕在线观看| 国产淫语在线视频| 日韩三级伦理在线观看| 午夜福利视频在线观看免费| 精品一区二区免费观看| 久久久久久久国产电影| 中文字幕人妻熟女乱码| 黄色 视频免费看| 亚洲精品乱码久久久久久按摩| 99九九在线精品视频| 久久久久精品人妻al黑| 色视频在线一区二区三区| 亚洲国产看品久久| 国产成人精品婷婷| videos熟女内射| 看非洲黑人一级黄片| 青春草国产在线视频| 免费观看在线日韩| 嫩草影院入口| 精品酒店卫生间| 青春草亚洲视频在线观看| 国产免费又黄又爽又色| 国产精品国产三级国产av玫瑰| 熟妇人妻不卡中文字幕| 最黄视频免费看| 国产精品国产三级国产专区5o| 在线看a的网站| 亚洲婷婷狠狠爱综合网| 国产成人精品在线电影| 国产av国产精品国产| 午夜福利,免费看| 欧美少妇被猛烈插入视频| 巨乳人妻的诱惑在线观看| 一级毛片 在线播放| 久久人人97超碰香蕉20202| 欧美日韩视频精品一区| 丝袜在线中文字幕| 黄片无遮挡物在线观看| 热re99久久精品国产66热6| 91午夜精品亚洲一区二区三区| www日本在线高清视频| 亚洲人成77777在线视频| 亚洲 欧美一区二区三区| 国产精品不卡视频一区二区| 成人18禁高潮啪啪吃奶动态图| 人妻 亚洲 视频| 又粗又硬又长又爽又黄的视频| 新久久久久国产一级毛片| 如日韩欧美国产精品一区二区三区| 国产成人aa在线观看| 亚洲欧美一区二区三区黑人 | 99热这里只有是精品在线观看| 一级,二级,三级黄色视频| 国产精品久久久久久精品电影小说| 国产成人精品在线电影| 亚洲国产最新在线播放| 在线天堂最新版资源| 99九九在线精品视频| 久久久久久久久久久免费av| 热re99久久国产66热| 国产精品.久久久| 亚洲精品av麻豆狂野| 国产一区二区三区综合在线观看 | 全区人妻精品视频| videossex国产| 国产成人精品在线电影| 日韩欧美精品免费久久| 香蕉丝袜av| 久久午夜福利片| 性高湖久久久久久久久免费观看| 美女福利国产在线| 色网站视频免费| 9191精品国产免费久久| 香蕉丝袜av| 午夜福利影视在线免费观看| 肉色欧美久久久久久久蜜桃| 国产老妇伦熟女老妇高清| 精品国产露脸久久av麻豆| 午夜老司机福利剧场| 最近中文字幕2019免费版| 午夜91福利影院| 日韩熟女老妇一区二区性免费视频| 久久97久久精品| 亚洲精品美女久久久久99蜜臀 | 精品熟女少妇av免费看| 男人爽女人下面视频在线观看| 亚洲一码二码三码区别大吗| 黄色视频在线播放观看不卡| 18在线观看网站| 麻豆乱淫一区二区| 亚洲熟女精品中文字幕| 中文字幕免费在线视频6| 免费观看a级毛片全部| 欧美成人精品欧美一级黄| 日韩中字成人| 亚洲国产精品国产精品| 亚洲精品色激情综合| 在线观看一区二区三区激情| 国产激情久久老熟女| 人妻 亚洲 视频| 亚洲精品国产色婷婷电影| 国产午夜精品一二区理论片| 有码 亚洲区| 国产色爽女视频免费观看| 边亲边吃奶的免费视频| 九九在线视频观看精品| 亚洲精品色激情综合| 春色校园在线视频观看| 91精品三级在线观看| 国产精品免费大片| 国产精品久久久久久精品古装| 国产女主播在线喷水免费视频网站| 18禁在线无遮挡免费观看视频| 久久久a久久爽久久v久久| 男人操女人黄网站| 最近手机中文字幕大全| 深夜精品福利| 亚洲国产欧美在线一区| 国产精品蜜桃在线观看| 国产福利在线免费观看视频| 高清不卡的av网站| 午夜免费观看性视频| 色婷婷av一区二区三区视频| 久久99热6这里只有精品| 免费女性裸体啪啪无遮挡网站| 久久精品久久精品一区二区三区| 日韩一区二区视频免费看| 色婷婷av一区二区三区视频| 啦啦啦啦在线视频资源| 亚洲欧美精品自产自拍| av国产精品久久久久影院| 国产色婷婷99| 久久精品国产自在天天线| 在线免费观看不下载黄p国产| 99精国产麻豆久久婷婷| 亚洲情色 制服丝袜| 久久av网站| 久久青草综合色| 成人亚洲精品一区在线观看| 春色校园在线视频观看| 日韩一本色道免费dvd| 青春草国产在线视频| 免费观看a级毛片全部| 韩国精品一区二区三区 | 男人舔女人的私密视频| 99久久中文字幕三级久久日本| 国产免费又黄又爽又色| 免费不卡的大黄色大毛片视频在线观看| 国产色婷婷99| 久久影院123| 国产一区二区三区综合在线观看 | 精品国产露脸久久av麻豆| 国产男女超爽视频在线观看| 国产探花极品一区二区| 午夜av观看不卡| 亚洲国产色片| 久久久国产精品麻豆| 亚洲av电影在线观看一区二区三区| 丝袜喷水一区| 观看av在线不卡| 黄网站色视频无遮挡免费观看| 国产女主播在线喷水免费视频网站| 成人无遮挡网站| 久久鲁丝午夜福利片| 久久久久人妻精品一区果冻| 国产淫语在线视频| av片东京热男人的天堂| 国产欧美日韩一区二区三区在线| 国产精品国产三级专区第一集| 又黄又粗又硬又大视频| 久久久国产精品麻豆| 天美传媒精品一区二区| 国产av一区二区精品久久| 国产精品人妻久久久影院| 日日啪夜夜爽| 极品人妻少妇av视频| 欧美97在线视频| 永久免费av网站大全| 国产在视频线精品| 天天躁夜夜躁狠狠久久av| 亚洲av综合色区一区| 欧美bdsm另类| 精品国产一区二区三区四区第35| 免费大片18禁| 亚洲av电影在线进入| 中文乱码字字幕精品一区二区三区| 亚洲一区二区三区欧美精品| 久久久久久久国产电影| 自拍欧美九色日韩亚洲蝌蚪91| 亚洲精品一二三| 久久国产亚洲av麻豆专区| 成年美女黄网站色视频大全免费| 黄网站色视频无遮挡免费观看| 亚洲欧洲国产日韩| 在线观看人妻少妇| 国产高清国产精品国产三级| 在线精品无人区一区二区三| 国产免费一区二区三区四区乱码| 国产精品 国内视频| 亚洲成人一二三区av| 日本vs欧美在线观看视频| 男人添女人高潮全过程视频| 黄色怎么调成土黄色| 欧美最新免费一区二区三区| 欧美日韩av久久| av免费观看日本| 国产亚洲av片在线观看秒播厂| 国产亚洲午夜精品一区二区久久| 黄色一级大片看看| 老司机亚洲免费影院| 日本与韩国留学比较| 97在线人人人人妻| 亚洲欧洲精品一区二区精品久久久 | 在线天堂中文资源库| 国产亚洲精品久久久com| 超色免费av| 亚洲av在线观看美女高潮| 精品久久国产蜜桃| 黄色配什么色好看| 国产片特级美女逼逼视频| 欧美日韩视频精品一区| 亚洲欧美色中文字幕在线| 国产高清国产精品国产三级| 国产男女超爽视频在线观看| 亚洲精品成人av观看孕妇| 草草在线视频免费看| 秋霞伦理黄片| 国产成人免费无遮挡视频| 永久免费av网站大全| 亚洲国产欧美日韩在线播放| 国产精品人妻久久久影院| 亚洲性久久影院| 9191精品国产免费久久| 2022亚洲国产成人精品| 亚洲少妇的诱惑av| 中国国产av一级| 国产av精品麻豆| 秋霞在线观看毛片| 亚洲av男天堂| 国产毛片在线视频| 国产在视频线精品| 亚洲美女黄色视频免费看| 精品亚洲成国产av| 久久午夜综合久久蜜桃| 插逼视频在线观看| 欧美3d第一页| 精品久久蜜臀av无| 日韩,欧美,国产一区二区三区| 在现免费观看毛片| 美女主播在线视频| 国产色婷婷99| 久久 成人 亚洲| 欧美精品一区二区大全| 亚洲国产成人一精品久久久| 国产亚洲午夜精品一区二区久久| 97超碰精品成人国产| 高清av免费在线| 亚洲精品色激情综合| 成人二区视频| 天堂中文最新版在线下载| 91精品国产国语对白视频| 欧美激情国产日韩精品一区| 制服人妻中文乱码| 亚洲国产看品久久| 国产亚洲午夜精品一区二区久久| 男人添女人高潮全过程视频| 久久人人爽人人爽人人片va| 两个人免费观看高清视频| 久久久久人妻精品一区果冻| 欧美激情国产日韩精品一区| 免费观看无遮挡的男女| 国产精品一区二区在线观看99| 亚洲精品国产av成人精品| 国产精品久久久久久久电影| 女性被躁到高潮视频| 伊人亚洲综合成人网| 99热这里只有是精品在线观看| 午夜av观看不卡| 韩国精品一区二区三区 | 亚洲精品成人av观看孕妇| 国产精品无大码| 国产深夜福利视频在线观看| 亚洲一级一片aⅴ在线观看| 日韩电影二区| 成人漫画全彩无遮挡| 看免费成人av毛片| 99九九在线精品视频| 日本免费在线观看一区| 国产亚洲一区二区精品| 大码成人一级视频| 国产精品.久久久| 亚洲五月色婷婷综合| 最近最新中文字幕免费大全7| 午夜福利,免费看| 老司机影院成人| 亚洲欧洲国产日韩| a级片在线免费高清观看视频| 精品少妇内射三级| 亚洲精品久久久久久婷婷小说| tube8黄色片| 亚洲精品av麻豆狂野| 亚洲精品视频女| 国产色爽女视频免费观看| 国产av国产精品国产| 亚洲av国产av综合av卡| 国产一区有黄有色的免费视频| 黑人猛操日本美女一级片| 亚洲精品美女久久av网站| 免费大片18禁| 一二三四在线观看免费中文在 | 亚洲美女黄色视频免费看| 亚洲精品456在线播放app| 桃花免费在线播放| 国产av一区二区精品久久| 国产成人免费无遮挡视频| 你懂的网址亚洲精品在线观看| 国产精品熟女久久久久浪| 亚洲国产精品一区二区三区在线| 9热在线视频观看99| 亚洲精品,欧美精品| 晚上一个人看的免费电影| 国产成人免费观看mmmm| 久久久精品免费免费高清| 久久青草综合色| 一级毛片黄色毛片免费观看视频| 国产成人aa在线观看| 哪个播放器可以免费观看大片| 精品人妻一区二区三区麻豆| av线在线观看网站| 777米奇影视久久| 人妻一区二区av| videossex国产|